{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=9", "query": { "condition": "Neurodegenerative Disease, Hereditary", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 1146, "total_pages": 115, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neurodegenerative+Disease%2C+Hereditary&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:15:41.974Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02273596", "title": "Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wilson Disease" ], "interventions": [ { "name": "ALXN1840", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-11-24", "completion_date": "2018-11-07", "has_results": true, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 4, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02273596" }, { "nct_id": "NCT04849741", "title": "A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alexander Disease" ], "interventions": [ { "name": "zilganersen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "2 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2021-06-01", "completion_date": "2034-07", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 4, "location_summary": "Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04849741" }, { "nct_id": "NCT01475383", "title": "Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tourette's Syndrome" ], "interventions": [ { "name": "PF-03654746", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2012-04", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2019-04-01", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "Manhasset, New York", "locations": [ { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475383" }, { "nct_id": "NCT00497159", "title": "A Study of the Novel Drug Dimebon in Patients With Huntington's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Huntington's Disease" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Dimebon", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Medivation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "29 Years", "maximum_age": null, "sex": "ALL", "summary": "29 Years and older" }, "enrollment_count": 91, "start_date": "2007-07", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00497159" }, { "nct_id": "NCT02104921", "title": "Innovative Ultrasound Technology in Neuromuscular Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Amyotrophic Lateral Sclerosis", "Muscular Dystrophy", "Radiculopathy", "Myopathy", "Polyneuropathy and Mononeuropathies", "Trauma Injury", "Orthopedic Disorder" ], "interventions": [], "intervention_types": [], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 223, "start_date": "2013-12-01", "completion_date": "2020-03-01", "has_results": false, "last_update_posted_date": "2022-03-11", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02104921" }, { "nct_id": "NCT06879665", "title": "TANDem-2: Closing the Gap to Interventions for TAND", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Caregivers of Individuals With TSC", "Tuberous Sclerosis Complex (TSC)" ], "interventions": [ { "name": "Well-Beans for Caregivers Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Vrije Universiteit Brussel", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-07-15", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06879665" }, { "nct_id": "NCT01907087", "title": "A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Jansky-Bielschowsky Disease", "Batten Disease", "Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2", "CLN2 Disease" ], "interventions": [ { "name": "BMN 190", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "3 Years to 15 Years" }, "enrollment_count": 24, "start_date": "2013-09", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2019-03-08", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907087" }, { "nct_id": "NCT02096471", "title": "MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN" ], "interventions": [ { "name": "PD-0325901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 19, "start_date": "2014-06", "completion_date": "2018-08-01", "has_results": true, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096471" }, { "nct_id": "NCT05902351", "title": "Natural History Study for Charcot Marie Tooth Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Charcot-Marie-Tooth Disease", "Charcot-Marie-Tooth", "Charcot-Marie-Tooth Disease, Type IA", "Charcot-Marie-Tooth Disease Type 2A", "Charcot-Marie-Tooth Disease Type 2", "Charcot-Marie-Tooth Disease, Type 2C", "Charcot-Marie-Tooth Disease Type 2A2B", "Charcot-Marie-Tooth Disease Type 2B2", "Charcot-Marie-Tooth Disease Type 2A1", "Charcot-Marie-Tooth Disease Type 4B1", "Charcot-Marie-Tooth Disease, Type IB", "Charcot-Marie-Tooth Disease Type 2B1", "Charcot-Marie-Tooth Disease Type 2U (Diagnosis)", "Charcot-Marie-Tooth Disease Type 4A", "Charcot-Marie-Tooth Disease, Type 4A, Axonal Form", "Charcot-Marie-Tooth Disease Type 2A2A", "Charcot-Marie-Tooth Disease Type 2S (Disorder)", "Charcot-Marie-Tooth Disease and Deafness", "Charcot-Marie-Tooth Disease Type 4B2", "Charcot-Marie-Tooth Disease Type 4H", "Charcot-Marie-Tooth Disease Type 1F", "Charcot-Marie-Tooth Disease Type 4C", "Charcot-Marie-Tooth Disease Type 4E", "Charcot-Marie-Tooth Disease Type 1D", "Charcot-Marie-Tooth Disease Type 2Q (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2A2", "Charcot-Marie-Tooth Disease Type 2N (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2B5", "Charcot-Marie-Tooth Disease Type 2D", "Charcot-Marie-Tooth Disease Type 4D", "Charcot-Marie-Tooth Disease Type 2K", "Charcot-Marie-Tooth Disease Type 2L (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2T", "Charcot-Marie-Tooth Disease Type 2I", "Charcot-Marie-Tooth Disease Type 2J", "Charcot-Marie-Tooth Disease Type 2E", "Charcot-Marie-Tooth Disease Type 2G", "Charcot-Marie-Tooth Disease Type 1C", "Charcot-Marie-Tooth Disease Type 2R", "Charcot-Marie-Tooth Disease Type 2O (Diagnosis)", "Charcot-Marie-Tooth Disease Type 2M", "Charcot-Marie-Tooth Disease Type 2P", "Charcot-Marie-Tooth Disease Type 2Y", "Charcot-Marie-Tooth Disease Type 4F (Diagnosis)", "Charcot-Marie-Tooth Disease Type 4B3", "Charcot-Marie-Tooth Disease Type 2H", "HNPP", "X-Linked Charcot-Marie-Tooth Disease", "Charcot Marie Tooth Disease (CMT)" ], "interventions": [], "intervention_types": [], "sponsor": "Hereditary Neuropathy Foundation", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 10000, "start_date": "2013-11-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902351" }, { "nct_id": "NCT02153931", "title": "Internet Support Group for Parents of a Child With Neurofibromatosis Type 1", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neurofibromatosis 1" ], "interventions": [], "intervention_types": [], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 33, "start_date": "2014-05-31", "completion_date": "2019-01-29", "has_results": false, "last_update_posted_date": "2019-01-31", "last_synced_at": "2026-10-15T12:15:41.974Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02153931" } ] }